Filing Flows › Comparisons › LYEL vs IBO
Lyell Immunopharma vs Impact Biomedical: LYEL and IBO compared
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $3K for Impact Biomedical (Q2 2026). Impact Biomedical is growing faster (-57% against -80% a year earlier).
Where the money goes: LYEL and IBO
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Impact Biomedical (IBO) · Q2 2026
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
| Lyell Immunopharma (LYEL) | Impact Biomedical (IBO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $3K | $3K |
| Revenue growth, Y/Y | -80% | -57% |
| Operating margin | n/m | n/m |
| Net earnings | −$45.5M | −$700K |
| Operating cash flow | −$34.6M | $470K |
Questions
Which is bigger, Lyell Immunopharma or Impact Biomedical?
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $3K for Impact Biomedical (Q2 2026).
Is Lyell Immunopharma or Impact Biomedical growing faster?
Impact Biomedical is growing faster (-57% against -80% a year earlier).
More: Lyell Immunopharma earnings · how Lyell Immunopharma makes money · Impact Biomedical earnings · how Impact Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.